[제약사 리포트] '이니바이오 빠진' 녹십자, 재무부담 줄였다

GC greenCross divested GC Wellbeing to its parent, removing its problematic stake in loss-making biotech firm Inibio while securing ~505 billion won for reinvestment. This strategic restructuring allows the company to concentrate capital on its core business—expanding production of the blood plasma therapeutic Aliglo and developing new subcutaneous formulations for U.S. market growth. The move reflects an industry trend toward portfolio optimization, where diversified pharma companies are reallocating resources from underperforming ventures to higher-impact therapeutic platforms.